Cargando…
Benchmarking tocilizumab use for giant cell arteritis
Autores principales: | Conway, Richard, Putman, Michael S, Mackie, Sarah L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115674/ https://www.ncbi.nlm.nih.gov/pubmed/35601271 http://dx.doi.org/10.1093/rap/rkac037 |
Ejemplares similares
-
Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022) -
Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013) -
Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective
por: Mackie, Sarah L, et al.
Publicado: (2021) -
Profile of tocilizumab and its potential in the treatment of giant cell arteritis
por: Mollan, Susan Patricia, et al.
Publicado: (2018) -
Vision loss in patients with giant cell arteritis treated with tocilizumab
por: Amsler, Jennifer, et al.
Publicado: (2021)